NOVATO, CA, (Monday, March 19, 2012) – Biosearch Technologies, Inc. (Biosearch), a leading supplier of sophisticated oligonucleotide components to the rapidly growing molecular diagnostics industry, today announced that the company has launched an improved Stellaris™ Probe Designer. The online, RNA FISH design software provides scientists with a means to design Stellaris RNA FISH probe sets against any mRNA or long noncoding RNA. Biosearch previously announced on August 5th 2010 that the company had licensed exclusive rights to a Single Molecule Fluorescent in situ hybridization technology based on detection of RNA. Biosearch owns the exclusive rights to manufacture, catalogue and sell validated RNA FISH probes, assays and kits into the Research, Applied Markets and IVD fields under the UMDNJ technologies and patent applications, and currently makes these products available as Stellaris RNA FISH probes.
Arjun Raj, co-inventor of Stellaris RNA~FISH probe technology expressed his satisfaction with the new development:
We're very excited to work with Biosearch to bring this major update to our Stellaris RNA FISH probe design software. Our new software performs a battery of bioinformatic tests to provide a set of probes that we have shown to reduce background, often dramatically, especially in higher eukaryotic organisms such as mouse and human. We have been having great success using this software to design probes against a variety of targets in our lab, including long non-coding RNA and other often difficult targets, and are excited about Biosearch bringing our tools to the broader scientific community. (Arjun Raj, University of Pennsylvania)
Sanjay Tyagi, also a co-inventor of the Stellaris RNA FISH technology, stated:
The availability of labeled sets of oligonucleotides as Stellaris probes for single molecule FISH from Biosearch has been immensely helpful for cell biologists. The single-molecule sensitivity in mRNA imaging has become accessible to all cell biologists who do not have to label and purify the probe sets themselves anymore. As evident from the flurry of recent of publications, this technology holds great promise in diverse fields ranging from developmental biology, neurobiology, RNA processing, to cancer biology. A second generation of the Stellaris probe designer software that exploits the knowledge of the genome sequences to substantially improve the specificity of the designed probes is an exciting new development. (Sanjay Tyagi, Public Health Research Institute Center, UMDNJ)
About UMDNJ and UMDNJ’s Office of Technology Transfer & Business Development
The University of Medicine and Dentistry of New Jersey (UMDNJ) is the nation's largest free-standing public health sciences university with more than 6,000 students attending the state's three medical schools, its only dental school, a graduate school of biomedical sciences, a school of health related professions, a school of nursing and its only school of public health on five campuses. Annually, there are more than two million patient visits at UMDNJ facilities and faculty practices at campuses in Newark, New Brunswick/Piscataway, Scotch Plains, Camden and Stratford. UMDNJ operates University Hospital, a Level I Trauma Center in Newark, and University Behavioral HealthCare, which provides a continuum of healthcare services with multiple locations throughout the state. UMDNJ’s Office of Technology Transfer & Business Development is the entity responsible for commercialization of UMDNJ’s intellectual property. The office works in partnership with UMDNJ faculty to identify, develop and commercialize promising academic discoveries.
For additional information about UMDNJ please visit www.umdnj.edu.
About Biosearch Technologies, Inc.
Biosearch Technologies, Inc. is a privately held, ISO 9001:2008 certified company, located in northern California. Founded in 1993, Biosearch is a leader in the design, development and manufacture of sophisticated oligonucleotide-based tools. Products include fluorophores (CAL Fluor®, Quasar® and Pulsar® dyes) and dark quenchers (Black Hole Quencher® dyes) to be included in custom-synthesized probe formats for real-time, quantitative PCR, Stellaris RNA FISH, and other genomic-based applications.
In addition to basic R&D applications, Biosearch now leverages its demonstrated expertise in fully assembled RUO kits and in the cGMP manufacture of oligonucleotide components for molecular diagnostic assays. Biosearch Technologies is registered with the FDA (registration number 300300905), and licensed by the State of California Department of Public Health (license number 55563) as a medical device manufacturer. As such, its GMP and Commercial Services manufacturing processes conform to all applicable cGMP requirements per21 CFR Part 820. Biosearch’s markets include pharmaceutical, in vitro diagnostic, biotechnology, ag/bio, environmental and food testing, public health, and biodefense sectors.
For additional information about Biosearch Technologies, Inc., contact email@example.com
or visit www.biosearchtech.com